Steroid Aromatase Inhibitors Versus Progestogens for nSAID-resistanced Late Stage Breast Cancer

A Randomized Study of Steroid Aromatase Inhibitors Versus Progestogens for Non-Steroid Aromatase Inhibitor-resistanced Late Stage Breast Cancer

NCT02161315•Tianjin Medical University Cancer Institute and Hospital

View on ClinicalTrials.gov

Summary

Steroid Aromatase Inhibitors and Non-Steroid Aromatase Inhibitors in Late Stage Breast Cancer is the recommended scheme in National Comprehensive Cancer Network (NCCN) guideline. In the past controlled clinical trials with small sample.

Detailed Description

A Randomized Study of Steroid Aromatase Inhibitors Versus Progestogens for Non-Steroid Aromatase Inhibitor-resistanced Late Stage Breast Cancer.The primary endpoints of the study is progression free survival (PFS). The secondary endpoints are overall response rate (ORR), overall survival (OS) and safety.

Eligibility

Age

All ages

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•1. Patients must be the postmenopausal women
•2. Patients must be diagnosed with advanced breast cancer by imageology，cytology or histopathology
•3. Immunohistochemistry shows ER and/or PR positive
•4. Patients ECOG score must be 0-2
•5. Drug resistant about Non-Steroid Aromatase Inhibitors

Exclusion Criteria

•1. Not suitable for endocrine therapy
•2. Have receive the standard Steroid Aromatase Inhibitors treatment
•3. Severe hepatic dysfunction

Locations (1)

Tianjin Medical University Cancer Institute and Hospital

Tianjin, Tianjin Municipality, China

Key Dates

Start Date

April 1, 2014

Primary Completion Date

November 1, 2016

Completion Date

December 1, 2016

Last Updated

December 22, 2015

Enrollment

ESTIMATED participants

Conditions

Carcinoma Breast Stage IV

Contacts

Yehui Shi, MD

CONTACT

022-23340123-1052 shiyehui@tom.com

Palliative Hypofractionated Radiotherapy in Advanced Incurable Breast Cancer

NCT03511781

Carcinoma Breast Stage IV

View study

COMPLETEDPHASE2

IMP321 (Eftilagimod Alpha) as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma

NCT02614833

Adenocarcinoma Breast Stage IV

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 22, 2015Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions